Key points are not available for this paper at this time.
To describe and compare real-world treatment patterns and clinical outcomes among individuals with immune thrombocytopenia (ITP) receiving second-line therapies (rituximab, romiplostim, or eltrombopag).
Liang et al. (Mon,) studied this question.